Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319735 · ClinicalTrials.gov registry record · Phase 2
Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas
A Phase 2 study of Esophageal Cancer, sponsored by Nasser Hanna, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 7
- Study locations
NCT00319735 is a Phase 2 study of Esophageal Cancer that has completed, run by Nasser Hanna, M.D.. The registered enrollment target is 41 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT00319735, a Phase 2 study of Esophageal Cancer, has completed, sponsored by Nasser Hanna, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 7
- Study locations
Study Summary
The interaction of epidermal growth factor receptor (EGFR) inhibitory agents such as cetuximab combined with radiation shows promising results. EGFR inhibitory agents also enhance radiation-induced apoptosis and inhibit radiation induced damage repair. These interactions may represent the principle effects that contribute to the synergy between EGFR and radiation. This trial will investigate the feasibility and activity of this combination in patients with surgically resectable disease.
Conditions Studied
Interventions
- PROCEDURE Surgery
- PROCEDURE Radiation Therapy
- PROCEDURE Tissue Sample
Study Locations (7)
Indiana
- Indiana University Cancer Center - Indianapolis
- Community Regional Cancer Center - Indianapolis
- AP&S Clinic - Terre Haute
Texas
- Texas Oncology, PA - Dallas
- University of Texas Southwestern Medical Center at Dallas - Dallas
Illinois
- Medical & Surgical Specialists, LLC - Galesburg
Missouri
- Siteman Cancer Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319735
The ClinicalTrials.gov registry entry for NCT00319735 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Nasser Hanna, M.D., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Surgery is the first listed.
NCT00319735 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Indiana, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT00319735 about?
NCT00319735 is a clinical study titled "Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas". The interaction of epidermal growth factor receptor (EGFR) inhibitory agents such as cetuximab combined with radiation shows promising results. EGFR inhibitory agents also enhance radiation-induced apoptosis and inhibit radiation induced damage repair. These interactions may represent the principle ...
What is the current status of trial NCT00319735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2006-04. Estimated completion is 2009-01.
What conditions does trial NCT00319735 study?
This clinical trial studies the following conditions: Esophageal Cancer.
What interventions are being tested in trial NCT00319735?
The interventions under investigation include: Surgery (PROCEDURE), Radiation Therapy (PROCEDURE), Tissue Sample (PROCEDURE).
Who is sponsoring clinical trial NCT00319735?
This trial is sponsored by Nasser Hanna, M.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00319735 being conducted?
This trial has 7 study locations across Illinois, Indiana, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
RECRUITING · Phase 2
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.